25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

6C1 (Cytomx) Stock Analysis
Buy, Hold or Sell?

Let's analyze Cytomx together

I guess you are interested in CytomX Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Cytomx’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Cytomx’s Price Targets

I'm going to help you getting a better view of CytomX Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about CytomX Therapeutics Inc

I send you an email if I find something interesting about CytomX Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Cytomx (30 sec.)










1.2. What can you expect buying and holding a share of Cytomx? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.63
Expected worth in 1 year
€1.42
How sure are you?
54.2%

+ What do you gain per year?

Total Gains per Share
€0.79
Return On Investment
23.3%

For what price can you sell your share?

Current Price per Share
€3.40
Expected price per share
€2.682 - €4.402
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cytomx (5 min.)




Live pricePrice per Share (EOD)
€3.40
Intrinsic Value Per Share
€1.76 - €2.29
Total Value Per Share
€2.39 - €2.92

2.2. Growth of Cytomx (5 min.)




Is Cytomx growing?

Current yearPrevious yearGrowGrow %
How rich?$119.9m-$40.3m$70.6m233.5%

How much money is Cytomx making?

Current yearPrevious yearGrowGrow %
Making money$11.9m$2.7m$9.2m76.9%
Net Profit Margin28.0%5.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Cytomx (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#303 / 843

Most Revenue
#181 / 843

Most Profit
#81 / 843
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cytomx?

Welcome investor! Cytomx's management wants to use your money to grow the business. In return you get a share of Cytomx.

First you should know what it really means to hold a share of Cytomx. And how you can make/lose money.

Speculation

The Price per Share of Cytomx is €3.4. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cytomx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cytomx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.63. Based on the TTM, the Book Value Change Per Share is €0.20 per quarter. Based on the YOY, the Book Value Change Per Share is €0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cytomx.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps0.000.0%0.072.1%0.020.5%0.000.1%-0.05-1.4%-0.06-1.6%
Usd Book Value Change Per Share0.5816.9%0.236.7%0.082.4%0.041.1%0.020.5%0.030.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.5816.9%0.236.7%0.082.4%0.041.1%0.020.5%0.030.9%
Usd Price Per Share2.18-1.30-1.65-1.55-2.97-3.85-
Price to Earnings Ratio-582.33--142.50-24.00--50.75--35.12--30.07-
Price-to-Total Gains Ratio3.78-10.46-143.70-42.10-42.79-32.08-
Price to Book Ratio2.99--106.87--7.22--38.03--18.35--11.69-
Price-to-Total Gains Ratio3.78-10.46-143.70-42.10-42.79-32.08-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.9338
Number of shares254
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.230.02
Usd Total Gains Per Share0.230.02
Gains per Quarter (254 shares)58.204.70
Gains per Year (254 shares)232.7818.82
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102332230199
2046645603828
3069868905647
4093192207566
501164115509485
60139713880113104
70162916210132123
80186218540151142
90209520870169161
100232823200188180

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%6.06.00.050.0%6.014.00.030.0%7.017.00.029.2%7.017.00.029.2%
Book Value Change Per Share4.00.00.0100.0%9.03.00.075.0%11.09.00.055.0%13.011.00.054.2%13.011.00.054.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.024.00.0%0.00.024.00.0%
Total Gains per Share4.00.00.0100.0%9.03.00.075.0%11.09.00.055.0%13.011.00.054.2%13.011.00.054.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of CytomX Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4970.198+151%0.070+605%0.031+1499%0.016+3006%0.026+1799%
Book Value Per Share--0.6280.159+296%-0.212+134%-0.118+119%0.111+467%0.150+320%
Current Ratio--4.1972.054+104%1.176+257%1.604+162%2.153+95%2.437+72%
Debt To Asset Ratio--0.3150.808-61%1.209-74%1.087-71%0.957-67%0.936-66%
Debt To Equity Ratio--0.4600.848-46%-+100%0.862-47%2.011-77%2.522-82%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--262372711.18096438603.635+172%34095947.190+670%40732343.922+544%222397664.786+18%335231412.263-22%
Eps---0.0010.063-101%0.015-106%0.002-133%-0.041+4947%-0.048+5800%
Ev To Sales Ratio--4.0681.245+227%0.234+1637%-0.970+124%2.779+46%5.616-28%
Free Cash Flow Per Share---0.083-0.102+23%-0.113+37%-0.094+14%-0.120+45%-0.098+18%
Free Cash Flow To Equity Per Share--0.4080.024+1617%-0.067+116%-0.037+109%-0.053+113%-0.036+109%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--2.292----------
Intrinsic Value_10Y_min--1.764----------
Intrinsic Value_1Y_max---0.290----------
Intrinsic Value_1Y_min---0.285----------
Intrinsic Value_3Y_max---0.476----------
Intrinsic Value_3Y_min---0.462----------
Intrinsic Value_5Y_max---0.184----------
Intrinsic Value_5Y_min---0.205----------
Market Cap560703880.400+45%310036263.280185465176.910+67%234712293.465+32%220838995.247+40%423166516.796-27%549036292.301-44%
Net Profit Margin---0.0080.280-103%0.054-115%-2.481+29958%-1.950+23520%-1.924+23214%
Operating Margin----0%-0%-2.5850%-2.0150%-1.9610%
Operating Ratio--1.0690.759+41%0.990+8%3.593-70%3.020-65%3.014-65%
Pb Ratio5.410+45%2.992-106.870+3672%-7.224+341%-38.026+1371%-18.351+713%-11.688+491%
Pe Ratio-1053.145-81%-582.327-142.503-76%24.000-2526%-50.747-91%-35.120-94%-30.068-95%
Price Per Share3.400+45%1.8801.125+67%1.423+32%1.339+40%2.566-27%3.329-44%
Price To Free Cash Flow Ratio-10.278-81%-5.683-2.942-48%-3.112-45%-5.541-3%-6.434+13%-5.483-4%
Price To Total Gains Ratio6.839+45%3.78110.456-64%143.696-97%42.099-91%42.788-91%32.082-88%
Quick Ratio--2.8281.237+129%0.938+202%0.987+187%0.917+208%1.031+174%
Return On Assets---0.0010.109-101%0.013-107%0.021-104%-0.011+1137%-0.017+1776%
Return On Equity---0.0010.234-101%--100%0.010-113%-0.104+7988%-0.131+10124%
Total Gains Per Share--0.4970.198+151%0.070+605%0.031+1499%0.016+3006%0.026+1799%
Usd Book Value--119909412.44130262601.713+296%-40397802.050+134%-22456723.295+119%21165646.288+467%28547068.452+320%
Usd Book Value Change Per Share--0.5750.229+151%0.082+605%0.036+1499%0.019+3006%0.030+1799%
Usd Book Value Per Share--0.7270.184+296%-0.245+134%-0.136+119%0.128+467%0.173+320%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--303565226.835111579464.406+172%39449010.898+670%47127321.918+544%257314098.157+18%387862743.988-22%
Usd Eps---0.0010.073-101%0.017-106%0.003-133%-0.047+4947%-0.055+5800%
Usd Free Cash Flow---15779922.678-19419404.844+23%-21571394.300+37%-18015578.390+14%-22842588.071+45%-17107249.507+8%
Usd Free Cash Flow Per Share---0.096-0.118+23%-0.131+37%-0.109+14%-0.139+45%-0.113+18%
Usd Free Cash Flow To Equity Per Share--0.4720.027+1617%-0.077+116%-0.043+109%-0.061+113%-0.042+109%
Usd Market Cap648734389.623+45%358711956.615214583209.685+67%271562123.538+32%255510717.501+40%489603659.933-27%635234990.192-44%
Usd Price Per Share3.934+45%2.1751.301+67%1.647+32%1.549+40%2.969-27%3.852-44%
Usd Profit---153999.24511995691.221-101%2771486.420-106%285248.602-154%-7883261.372+5019%-9178913.356+5860%
Usd Revenue--18657908.57635274827.153-47%29892103.528-38%27229283.243-31%23289285.882-20%22957387.508-19%
Usd Total Gains Per Share--0.5750.229+151%0.082+605%0.036+1499%0.019+3006%0.030+1799%
 EOD+6 -2MRQTTM+24 -11YOY+23 -123Y+26 -95Y+28 -710Y+26 -9

3.3 Fundamental Score

Let's check the fundamental score of CytomX Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1,053.145
Price to Book Ratio (EOD)Between0-15.410
Net Profit Margin (MRQ)Greater than0-0.008
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.828
Current Ratio (MRQ)Greater than14.197
Debt to Asset Ratio (MRQ)Less than10.315
Debt to Equity Ratio (MRQ)Less than10.460
Return on Equity (MRQ)Greater than0.15-0.001
Return on Assets (MRQ)Greater than0.05-0.001
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of CytomX Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.269
Ma 20Greater thanMa 503.030
Ma 50Greater thanMa 1002.479
Ma 100Greater thanMa 2002.180
OpenGreater thanClose3.400
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

Fundamental data was last updated by Penke on 2025-11-02 12:11:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Cytomx earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Cytomx to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -0.8%Β means thatΒ €-0.01 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CytomX Therapeutics Inc:

  • The MRQ is -0.8%. The company is not making a profit/loss.
  • The TTM is 28.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ-0.8%TTM28.0%-28.8%
TTM28.0%YOY5.4%+22.6%
TTM28.0%5Y-195.0%+223.0%
5Y-195.0%10Y-192.4%-2.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.8%-78.6%+77.8%
TTM28.0%-163.3%+191.3%
YOY5.4%-187.9%+193.3%
3Y-248.1%-262.6%+14.5%
5Y-195.0%-338.6%+143.6%
10Y-192.4%-470.4%+278.0%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Cytomx is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Cytomx to theΒ Biotechnology industry mean.
  • -0.1% Return on Assets means thatΒ Cytomx generatedΒ €0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CytomX Therapeutics Inc:

  • The MRQ is -0.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 10.9%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ-0.1%TTM10.9%-11.0%
TTM10.9%YOY1.3%+9.6%
TTM10.9%5Y-1.1%+12.0%
5Y-1.1%10Y-1.7%+0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.1%-11.8%+11.7%
TTM10.9%-11.5%+22.4%
YOY1.3%-11.2%+12.5%
3Y2.1%-12.0%+14.1%
5Y-1.1%-11.6%+10.5%
10Y-1.7%-13.7%+12.0%
4.3.1.3. Return on Equity

Shows how efficient Cytomx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Cytomx to theΒ Biotechnology industry mean.
  • -0.1% Return on Equity means Cytomx generated €0.00Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CytomX Therapeutics Inc:

  • The MRQ is -0.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 23.4%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ-0.1%TTM23.4%-23.6%
TTM23.4%YOY-+23.4%
TTM23.4%5Y-10.4%+33.8%
5Y-10.4%10Y-13.1%+2.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.1%-13.8%+13.7%
TTM23.4%-14.7%+38.1%
YOY--15.1%+15.1%
3Y1.0%-16.7%+17.7%
5Y-10.4%-16.9%+6.5%
10Y-13.1%-19.5%+6.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of CytomX Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Cytomx is operatingΒ .

  • Measures how much profit Cytomx makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Cytomx to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CytomX Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-201.5%+201.5%
5Y-201.5%10Y-196.1%-5.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--164.5%+164.5%
TTM--266.6%+266.6%
YOY--248.7%+248.7%
3Y-258.5%-248.8%-9.7%
5Y-201.5%-331.9%+130.4%
10Y-196.1%-501.5%+305.4%
4.3.2.2. Operating Ratio

Measures how efficient Cytomx is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 1.07 means that the operating costs are €1.07 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of CytomX Therapeutics Inc:

  • The MRQ is 1.069. The company is inefficient in keeping operating costs low. -1
  • The TTM is 0.759. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ1.069TTM0.759+0.310
TTM0.759YOY0.990-0.231
TTM0.7595Y3.020-2.260
5Y3.02010Y3.014+0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0691.898-0.829
TTM0.7592.722-1.963
YOY0.9902.848-1.858
3Y3.5933.562+0.031
5Y3.0204.571-1.551
10Y3.0146.306-3.292
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of CytomX Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cytomx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 4.20Β means the company has €4.20 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of CytomX Therapeutics Inc:

  • The MRQ is 4.197. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.054. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ4.197TTM2.054+2.143
TTM2.054YOY1.176+0.878
TTM2.0545Y2.153-0.099
5Y2.15310Y2.437-0.284
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1973.272+0.925
TTM2.0543.570-1.516
YOY1.1764.010-2.834
3Y1.6044.376-2.772
5Y2.1535.701-3.548
10Y2.4376.070-3.633
4.4.3.2. Quick Ratio

Measures if Cytomx is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Cytomx to theΒ Biotechnology industry mean.
  • A Quick Ratio of 2.83Β means the company can pay off €2.83 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CytomX Therapeutics Inc:

  • The MRQ is 2.828. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.237. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ2.828TTM1.237+1.590
TTM1.237YOY0.938+0.300
TTM1.2375Y0.917+0.320
5Y0.91710Y1.031-0.114
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8282.909-0.081
TTM1.2373.149-1.912
YOY0.9383.831-2.893
3Y0.9874.393-3.406
5Y0.9175.686-4.769
10Y1.0316.469-5.438
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of CytomX Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of CytomxΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Cytomx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.32Β means that Cytomx assets areΒ financed with 31.5% credit (debt) and the remaining percentage (100% - 31.5%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of CytomX Therapeutics Inc:

  • The MRQ is 0.315. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.808. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.315TTM0.808-0.493
TTM0.808YOY1.209-0.400
TTM0.8085Y0.957-0.149
5Y0.95710Y0.936+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3150.349-0.034
TTM0.8080.364+0.444
YOY1.2090.335+0.874
3Y1.0870.353+0.734
5Y0.9570.348+0.609
10Y0.9360.379+0.557
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Cytomx is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Cytomx to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 46.0% means that company has €0.46 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CytomX Therapeutics Inc:

  • The MRQ is 0.460. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.848. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.460TTM0.848-0.388
TTM0.848YOY-+0.848
TTM0.8485Y2.011-1.163
5Y2.01110Y2.522-0.511
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4600.410+0.050
TTM0.8480.448+0.400
YOY-0.431-0.431
3Y0.8620.473+0.389
5Y2.0110.474+1.537
10Y2.5220.523+1.999
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Cytomx generates.

  • Above 15 is considered overpriced butΒ always compareΒ Cytomx to theΒ Biotechnology industry mean.
  • A PE ratio of -582.33 means the investor is paying €-582.33Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CytomX Therapeutics Inc:

  • The EOD is -1,053.145. Based on the earnings, the company is expensive. -2
  • The MRQ is -582.327. Based on the earnings, the company is expensive. -2
  • The TTM is -142.503. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1,053.145MRQ-582.327-470.818
MRQ-582.327TTM-142.503-439.824
TTM-142.503YOY24.000-166.503
TTM-142.5035Y-35.120-107.383
5Y-35.12010Y-30.068-5.051
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1,053.145-2.703-1,050.442
MRQ-582.327-2.294-580.033
TTM-142.503-2.664-139.839
YOY24.000-3.568+27.568
3Y-50.747-3.737-47.010
5Y-35.120-5.932-29.188
10Y-30.068-6.842-23.226
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of CytomX Therapeutics Inc:

  • The EOD is -10.278. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.683. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.942. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.278MRQ-5.683-4.595
MRQ-5.683TTM-2.942-2.741
TTM-2.942YOY-3.112+0.170
TTM-2.9425Y-6.434+3.492
5Y-6.43410Y-5.483-0.951
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.278-3.420-6.858
MRQ-5.683-2.907-2.776
TTM-2.942-3.843+0.901
YOY-3.112-4.299+1.187
3Y-5.541-5.307-0.234
5Y-6.434-8.253+1.819
10Y-5.483-9.824+4.341
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Cytomx is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.99 means the investor is paying €2.99Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of CytomX Therapeutics Inc:

  • The EOD is 5.410. Based on the equity, the company is overpriced. -1
  • The MRQ is 2.992. Based on the equity, the company is underpriced. +1
  • The TTM is -106.870. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.410MRQ2.992+2.419
MRQ2.992TTM-106.870+109.862
TTM-106.870YOY-7.224-99.646
TTM-106.8705Y-18.351-88.519
5Y-18.35110Y-11.688-6.663
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.4102.316+3.094
MRQ2.9922.061+0.931
TTM-106.8702.230-109.100
YOY-7.2242.489-9.713
3Y-38.0262.654-40.680
5Y-18.3513.761-22.112
10Y-11.6884.406-16.094
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets175,057
Total Liabilities55,147
Total Stockholder Equity119,910
 As reported
Total Liabilities 55,147
Total Stockholder Equity+ 119,910
Total Assets = 175,057

Assets

Total Assets175,057
Total Current Assets164,621
Long-term Assets10,436
Total Current Assets
Cash And Cash Equivalents 49,041
Short-term Investments 109,046
Net Receivables 1,869
Other Current Assets 4,665
Total Current Assets  (as reported)164,621
Total Current Assets  (calculated)164,621
+/-0
Long-term Assets
Property Plant Equipment 7,893
Goodwill 949
Intangible Assets 510
Long-term Assets Other 1,084
Long-term Assets  (as reported)10,436
Long-term Assets  (calculated)10,436
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities39,223
Long-term Liabilities15,924
Total Stockholder Equity119,910
Total Current Liabilities
Accounts payable 227
Total Current Liabilities  (as reported)39,223
Total Current Liabilities  (calculated)227
+/- 38,996
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt6,885
Long-term Liabilities Other 4,241
Long-term Liabilities  (as reported)15,924
Long-term Liabilities  (calculated)11,126
+/- 4,798
Total Stockholder Equity
Total Stockholder Equity (as reported)119,910
Total Stockholder Equity (calculated)0
+/- 119,910
Other
Capital Stock2
Common Stock Shares Outstanding 164,911
Net Invested Capital 119,910
Net Working Capital 125,398
Property Plant and Equipment Gross 7,893



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
372,544
341,282
436,662
402,479
375,182
358,663
434,158
402,440
371,233
339,411
296,825
260,086
226,492
260,891
234,630
209,185
221,167
201,792
184,687
159,219
138,981
120,533
98,497
175,057
175,05798,497120,533138,981159,219184,687201,792221,167209,185234,630260,891226,492260,086296,825339,411371,233402,440434,158358,663375,182402,479436,662341,282372,544
   > Total Current Assets 
334,778
303,335
400,066
366,566
340,305
324,013
400,008
271,005
240,998
310,301
268,444
232,770
200,280
237,102
212,277
187,801
201,204
182,936
167,247
143,080
124,180
107,305
86,628
164,621
164,62186,628107,305124,180143,080167,247182,936201,204187,801212,277237,102200,280232,770268,444310,301240,998271,005400,008324,013340,305366,566400,066303,335334,778
       Cash And Cash Equivalents 
164,646
188,425
143,286
291,388
176,810
191,859
329,666
256,146
236,284
205,530
163,488
129,290
95,036
193,650
56,357
57,536
26,024
17,171
36,185
43,247
40,576
38,052
47,604
49,041
49,04147,60438,05240,57643,24736,18517,17126,02457,53656,357193,65095,036129,290163,488205,530236,284256,146329,666191,859176,810291,388143,286188,425164,646
       Short-term Investments 
161,067
107,720
104,636
55,013
144,266
124,260
64,130
10,031
5
99,696
99,042
98,875
99,254
0
148,145
123,322
168,086
157,338
114,099
93,935
77,012
62,571
32,282
109,046
109,04632,28262,57177,01293,935114,099157,338168,086123,322148,145099,25498,87599,04299,696510,03164,130124,260144,26655,013104,636107,720161,067
       Net Receivables 
7
13
143,071
13,267
13,604
798
756
931
887
790
1,016
1,014
1,712
35,986
1,090
1,903
2,419
3,432
13,177
2,775
3,352
3,103
1,956
1,869
1,8691,9563,1033,3522,77513,1773,4322,4191,9031,09035,9861,7121,0141,01679088793175679813,60413,267143,071137
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
4,898
3,591
4,278
7,466
6,685
5,040
4,675
4,995
3,786
3,123
3,240
3,579
4,786
4,665
4,6654,7863,5793,2403,1233,7864,9954,6755,0406,6857,4664,2783,5914,8980000000000
   > Long-term Assets 
37,766
37,947
36,596
35,913
34,877
34,650
34,150
131,435
130,235
29,110
28,381
27,316
26,212
23,789
22,353
21,384
19,963
18,856
17,440
16,139
14,801
13,228
11,869
10,436
10,43611,86913,22814,80116,13917,44018,85619,96321,38422,35323,78926,21227,31628,38129,110130,235131,43534,15034,65034,87735,91336,59637,94737,766
       Property Plant Equipment 
33,176
32,754
32,075
31,428
30,429
29,445
28,908
27,660
26,441
25,322
24,629
23,607
22,540
21,021
19,621
18,625
17,244
16,178
14,801
13,541
12,135
10,603
9,284
7,893
7,8939,28410,60312,13513,54114,80116,17817,24418,62519,62121,02122,54023,60724,62925,32226,44127,66028,90829,44530,42931,42832,07532,75433,176
       Goodwill 
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949949949949949949949949949949949949949949949949949949949949949949949949
       Long Term Investments 
0
0
0
0
0
0
0
99,914
99,969
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000099,96999,9140000000
       Intangible Assets 
1,349
1,312
1,276
1,240
1,203
1,167
1,130
1,094
1,057
1,021
984
948
911
875
839
802
766
729
693
656
620
583
547
510
5105475836206566937297668028398759119489841,0211,0571,0941,1301,1671,2031,2401,2761,3121,349
       Other Assets 
2,292
2,932
2,296
2,296
2,296
3,089
3,163
1,818
1,819
1,818
1,819
1,812
1,812
944
0
1,008
0
0
0
0
0
0
0
0
000000001,00809441,8121,8121,8191,8181,8191,8183,1633,0892,2962,2962,2962,9322,292
> Total Liabilities 
290,435
290,169
366,895
343,650
327,118
308,860
288,136
271,487
259,559
250,032
228,631
211,378
198,018
346,642
321,267
294,212
272,405
249,239
216,367
190,446
162,433
120,989
73,448
55,147
55,14773,448120,989162,433190,446216,367249,239272,405294,212321,267346,642198,018211,378228,631250,032259,559271,487288,136308,860327,118343,650366,895290,169290,435
   > Total Current Liabilities 
76,126
85,590
106,001
98,785
102,033
100,924
98,049
93,377
99,772
106,316
102,766
99,439
97,841
152,608
151,262
141,377
146,790
155,913
144,536
142,858
119,228
85,772
50,201
39,223
39,22350,20185,772119,228142,858144,536155,913146,790141,377151,262152,60897,84199,439102,766106,31699,77293,37798,049100,924102,03398,785106,00185,59076,126
       Accounts payable 
4,550
4,158
3,782
4,927
3,643
2,996
2,582
1,755
1,516
2,818
1,721
1,920
5,176
2,809
2,203
1,029
1,705
1,458
1,964
611
1,422
1,088
276
227
2272761,0881,4226111,9641,4581,7051,0292,2032,8095,1761,9201,7212,8181,5161,7552,5822,9963,6434,9273,7824,1584,550
       Other Current Liabilities 
51,080
51,381
73,866
72,711
74,445
74,869
76,636
72,369
73,089
69,262
70,013
65,787
65,201
122,894
126,867
120,310
0
0
0
0
0
0
0
0
00000000120,310126,867122,89465,20165,78770,01369,26273,08972,36976,63674,86974,44572,71173,86651,38151,080
   > Long-term Liabilities 
214,309
204,579
260,894
244,865
225,085
207,936
190,087
178,110
159,787
143,716
125,865
111,939
100,177
194,034
170,005
152,835
125,615
93,326
71,831
47,588
43,205
35,217
23,247
15,924
15,92423,24735,21743,20547,58871,83193,326125,615152,835170,005194,034100,177111,939125,865143,716159,787178,110190,087207,936225,085244,865260,894204,579214,309
       Capital Lease Obligations Min Short Term Debt
28,340
27,681
27,008
26,321
25,621
24,870
24,104
23,323
22,526
21,674
20,807
19,921
19,016
18,057
17,076
16,076
15,055
13,974
12,872
11,746
10,597
9,385
8,149
6,885
6,8858,1499,38510,59711,74612,87213,97415,05516,07617,07618,05719,01619,92120,80721,67422,52623,32324,10424,87025,62126,32127,00827,68128,340
       Other Liabilities 
188,688
179,708
236,789
221,542
202,560
186,261
169,280
158,189
140,770
125,660
108,788
95,863
85,122
180,059
0
141,089
0
0
0
0
0
0
0
0
00000000141,0890180,05985,12295,863108,788125,660140,770158,189169,280186,261202,560221,542236,789179,708188,688
> Total Stockholder Equity
82,109
51,113
69,767
58,829
48,064
49,803
146,022
130,953
111,674
89,379
68,194
48,708
28,474
-85,751
-86,637
-85,027
-51,238
-47,447
-31,680
-31,227
-23,452
-456
25,049
119,910
119,91025,049-456-23,452-31,227-31,680-47,447-51,238-85,027-86,637-85,75128,47448,70868,19489,379111,674130,953146,02249,80348,06458,82969,76751,11382,109
   Common Stock
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
1
0
0
0
0
0
0
0
0
000000001011111111111111
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
110
57
336
16
-47
-47
-43
15
52
-242
-919
-1,162
-795
10
0
35
0
0
0
0
0
0
0
0
0000000035010-795-1,162-919-2425215-43-47-471633657110



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue138,103
Cost of Revenue--
Gross Profit-138,103
 
Operating Income (+$)
Gross Profit-
Operating Expense-113,108
Operating Income24,995-113,108
 
Operating Expense (+$)
Research Development83,382
Selling General Administrative29,726
Selling And Marketing Expenses-
Operating Expense113,108113,108
 
Net Interest Income (+$)
Interest Income7,136
Interest Expense--
Other Finance Cost-0
Net Interest Income7,136
 
Pretax Income (+$)
Operating Income24,995
Net Interest Income7,136
Other Non-Operating Income Expenses-
Income Before Tax (EBT)32,09325,033
EBIT - interestExpense = 0
31,869
31,869
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-32,093
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax32,093
Tax Provision-224
Net Income From Continuing Ops31,86931,869
Net Income31,869
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-38-7,136
 

Technical Analysis of Cytomx
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cytomx. The general trend of Cytomx is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cytomx's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Cytomx Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of CytomX Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.402.

The bearish price targets are: 3.248 > 2.766 > 2.682.

Know someone who trades $6C1? Share this with them.πŸ‘‡

CytomX Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of CytomX Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

CytomX Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of CytomX Therapeutics Inc. The current macd is 0.26827203.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cytomx price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Cytomx. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Cytomx price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
CytomX Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCytomX Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of CytomX Therapeutics Inc. The current adx is 38.23.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cytomx shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
CytomX Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of CytomX Therapeutics Inc. The current sar is 2.9187968.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
CytomX Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of CytomX Therapeutics Inc. The current rsi is 61.27. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
CytomX Therapeutics Inc Daily Relative Strength Index (RSI) ChartCytomX Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of CytomX Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cytomx price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
CytomX Therapeutics Inc Daily Stochastic Oscillator ChartCytomX Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of CytomX Therapeutics Inc. The current cci is 102.27.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
CytomX Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCytomX Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of CytomX Therapeutics Inc. The current cmo is 19.72.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
CytomX Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCytomX Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of CytomX Therapeutics Inc. The current willr is -39.96212121.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cytomx is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
CytomX Therapeutics Inc Daily Williams %R ChartCytomX Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of CytomX Therapeutics Inc.

CytomX Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of CytomX Therapeutics Inc. The current atr is 0.17017708.

CytomX Therapeutics Inc Daily Average True Range (ATR) ChartCytomX Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of CytomX Therapeutics Inc. The current obv is 32,286.

CytomX Therapeutics Inc Daily On-Balance Volume (OBV) ChartCytomX Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of CytomX Therapeutics Inc. The current mfi is 52.13.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
CytomX Therapeutics Inc Daily Money Flow Index (MFI) ChartCytomX Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for CytomX Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-06-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-11 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-15 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-21 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-24 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-30 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-31 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-01 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-04 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-05 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-07 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-11 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-12 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-13 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-18 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-19 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-25 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-03 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-08 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-10 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-15 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-16 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-18 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-09-19 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-22 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-24 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-09-25 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-26 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-01 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-07 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-13 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-17 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-20 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-21 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-22 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-24 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-10-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-30 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-10-31 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-11-03 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-11-04 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-11-05 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-11-06 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-11-07 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

CytomX Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of CytomX Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.269
Ma 20Greater thanMa 503.030
Ma 50Greater thanMa 1002.479
Ma 100Greater thanMa 2002.180
OpenGreater thanClose3.400
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cytomx with someone you think should read this too:
  • Are you bullish or bearish on Cytomx? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cytomx? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about CytomX Therapeutics Inc

I send you an email if I find something interesting about CytomX Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about CytomX Therapeutics Inc.

Receive notifications about CytomX Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.